Page 103 - 《中国药房》2026年6期

ger for mirtazapine：a discontinuation syndrome[J]. J Pain [14] LI Z P，DANIEL S，FUJIOKA K，et al. Obesity among
Palliat Care Pharmacother，2021，35（2）：113-116. Asian American people in the United States：a review[J].
[ 2 ] TAKAKI M，ISHIKAWA R，SAKAMOTO S，et al. Mir‐ Obesity，2023，31（2）：316-328.
tazapine was effective for a patient with benzodiazepine [15] LAWRENCE E G，ZAHID U，THOMSON A C，et al. Psy‐
dependence[J]. Clin Neuropharmacol，2022，45（1）：11-12. chosocial and demographic factors associated with physi‐
[ 3 ] HIERONYMUS F，LISINSKI A，ERIKSSON E. Impact cal multimorbidity in severe mental illness：a systematic
of sedative and appetite-increasing properties on the appa- review[J]. Schizophr Bull，2025：sbaf128.
rent antidepressant efficacy of mirtazapine，selective sero‐ [16] HOLE K，GANGSØ S，JENSSTUEN Å T，et al. Effect of
tonin reuptake inhibitors and amitriptyline：an item-based， CYP2D6 genotype on duloxetine serum concentration[J].
patient-level meta-analysis[J]. EClinicalMedicine，2024， Basic Clin Pharmacol Toxicol，2024，134（1）：186-192.
77：102904. [17] 谯明，朱毅，靳路，等 . 度洛西汀在抑郁症患者中血药浓
[ 4 ] HIEMKE C，BERGEMANN N，CLEMENT H W，et al. 度/剂量比的影响因素研究[J]. 中国医院用药评价与分
Consensus guidelines for therapeutic drug monitoring in 析，2024，24（6）：672-675.
neuropsychopharmacology：update 2017[J]. Pharmacopsy‐ [18] DUBRALL D，CHRIST P，BÖHME M，et al. Analysis of
chiatry，2018，51（1/2）：e1. drug-drug interactions between psychiatric drugs in spon‐
[ 5 ] MEHRA A，SACHDEVA V，KHANNA J，et al. Mirtazapine taneous adverse drug reaction reports from EudraVigilance
revisited：new therapeutic perspectives and formulation [J]. Naunyn Schmiedebergs Arch Pharmacol，2026：1-18
advances[J]. Naunyn Schmiedebergs Arch Pharmacol， （2026-01-22）[2026-02-13]. https：//pubmed.ncbi.nlm.nih.
2026，399（2）：1689-1710. gov/41569311. DOI：10.1007/s00210-025-04956-5.
[ 6 ] TVEIT K，HERMANN M，NILSEN R M，et al. Age of on‐ [19] HOLE K，MOLDEN E. Association between CYP2D6
set for increased dose-adjusted serum concentrations of an‐ genotypes and serum concentrations of mirtazapine and
tidepressants and association with sex and genotype：an mianserin[J]. Basic Clin Pharmacol Toxicol，2025，136
observational study of 34 777 individuals[J]. Eur J Clin （4）：e70013.
Pharmacol，2024，80（3）：435-444. [20] RELLING M V，KLEIN T E. CPIC：clinical pharmacoge‐
[ 7 ] OGAWA R，ECHIZEN H. Drug-drug interaction profiles netics implementation consortium of the pharmacogeno-
of proton pump inhibitors[J]. Clin Pharmacokinet，2010， mics research network[J]. Clin Pharmacol Ther，2011，89
49（8）：509-533. （3）：464-467.
[ 8 ] 张毅，苗瑜，张玉平，等. 米氮平治疗抑郁症患者的疗效、 [21] NIERYCHLEWSKI K，PAAL M，MEINZER S，et al. Op‐
安全性分析及与血药浓度的相关性研究[J]. 精神医学杂 timizing therapeutic drug monitoring of mirtazapine：ap‐
志，2025，38（3）：275-280. plying therapeutic reference range，concentration：dose
[ 9 ] KLEINE SCHAARS K，NIJENHUIS M，SOREE B，et al. ratio/dose-related concentration，and metabolic ratio in a
Dutch Pharmacogenetics Working Group（DPWG） guide‐ naturalistic setting[J]. Eur J Clin Pharmacol，2025，81
line for the gene：drug interaction between CYP2D6 and （11）：1677-1687.
CYP2C19 and tricyclic antidepressants[J]. Eur J Hum [22] ZASTROZHIN M，SKRYABIN V，SYCHEV D，et al.
Genet，2026，34（3）：379-386. The influence of concentration of micro-RNA hsa-miR-
[10] ZANGER U M，SCHWAB M. Cytochrome P450 enzymes 370-3p and CYP2D6*4 on equilibrium concentration of
in drug metabolism：regulation of gene expression，en‐ mirtazapine in patients with major depressive disorder[J].
zyme activities，and impact of genetic variation[J]. Phar‐ Eur Psychiatr，2021，64（Suppl. 1）：S454-S455.
macol Ther，2013，138（1）：103-141. [23] MILOSAVLJEVIC F，BUKVIC N，PAVLOVIC Z，et al.
[11] American Psychiatric Association. Diagnostic and statisti‐ Association of CYP2C19 and CYP2D6 poor and interme‐
cal manual of mental disorders[M].5th edition. Arlington， diate metabolizer status with antidepressant exposure：a
VA：American Psychiatric Publishing，2013：5-18. systematic review and meta-analysis[J]. JAMA Psychia‐
[12] 国家药典委员会. 中华人民共和国药典：四部[M]：2020 try，2021，78（3）：270-280.
年版.北京：中国医药科技出版社，2020：466-472. [24] MAULANA Y，TORO JIMENEZ R，TWESIGOMWE D，
[13] KIM H，JEON S，KANG M G. P03-05 a comprehensive et al. The variation landscape of CYP2D6 in a multi-
dataset and machine learning benchmarks for CYP2D6 ethnic Asian population[J]. Sci Rep，2024，14（1）：16725.
variant-drug metabolic activity prediction[J]. Toxicol Lett， （收稿日期：2025-11-06 修回日期：2026-02-13）
2025，411：S72-S73. （编辑：舒安琴）

中国药房 2026年第37卷第6期 China Pharmacy 2026 Vol. 37 No. 6 · 781 ·